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Abstract: Atherosclerosis is a progressive, inflammatory cardiovascular disorder characterized by 
the development of lipid‐filled plaques within arteries. Endothelial cell dysfunction in the walls of 
blood vessels results in an increase in vascular permeability, alteration of the components of the 
extracellular matrix, and retention of LDL in the sub‐endothelial space, thereby accelerating plaque 
formation. Epigenetic modification by SUMOylation can influence the surface interactions of target 
proteins and affect cellular functionality, thereby regulating multiple cellular processes. Small 
ubiquitin‐like modifier (SUMO) can modulate NFκB and other proteins such as p53, KLF, and ERK5, 
which have critical roles in atherogenesis. Furthermore, SUMO regulates leukocyte recruitment and 
cytokine release and the expression of adherence molecules. In this review, we discuss the 
regulation by SUMO and SUMOylation modifications of proteins and pathways involved in 
atherosclerosis. 
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1. Introduction 
The development and rupture of atherosclerotic plaques is the most important cause of major 
clinical cardiovascular events including myocardial infarction and stroke, which were responsible for 
one‐quarter of the deaths worldwide in 2010 [1–3]. Atherosclerosis is a chronic, inflammatory, slowly 
progressing disorder of the arterial wall, characterized by the accumulation of lipids in the walls of 
large and medium‐sized arteries and infiltration of immune cells, leading to the development of 
atherosclerotic plaques [2,4]. Atherosclerosis can develop asymptomatically for decades until rupture 
or erosion of the plaque occurs, resulting in intravascular thrombosis, ischemia, and necrosis [5]. 
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Numerous studies have demonstrated that high circulating concentrations of low‐density 
lipoproteins (LDL) and the cholesterol carried within this lipoprotein accelerate the formation of 
atherosclerotic plaques [6]. Dyslipidemia and an imbalance in the influx and efflux of cellular 
cholesterol leads to accumulation, oxidation, and finally deposition of LDL and LDL‐like particles in 
the vascular wall and is associated with endothelial cell activation in sites prone to atherosclerotic 
lesions [7–10]. Endothelial cell dysfunction occurs commonly in regions of the vessel that experience 
turbulent blood‐flow. Plaque formation is associated with increased vascular permeability, altered 
composition of the extracellular matrix, and retention of LDL in the sub‐endothelial space [6]. 
Activated endothelial cells up‐regulate the expression of cell adherence molecules and release 
chemokines, leading to the recruitment and infiltration of immune cells, especially circular 
monocytes and T‐lymphocytes [6,7,11–13]. LDL particles that become trapped in the intima of the 
vessel are modified by lipase and protease enzymes and oxidized by myeloperoxidase, lipoxygenase, 
and reactive oxygen species. They are then taken up by monocytes via scavenger receptors and by 
resident macrophages in the arterial lumen. As cholesterol esters accumulate as droplets in 
macrophages, these cells become “foam cells” that are a hallmark of the early stages of plaques 
[4,6,11,14–16]. Oxidized LDL (oxLDL) is a potential damage‐associated molecular pattern (DAMP) 
and induces an inflammatory response. 
Foam cells secrete inflammatory cytokines (interleukins and TNF‐α) and chemokines (for 
example, monocyte chemoattractant protein‐1 or MCP‐1), and these events lead to exacerbation of 
the local inflammatory response. As the disease progresses, smooth muscle cells migrate to the intima 
of the affected vessels and initiate the secretion of extracellular matrix components that result in the 
formation of a fibrotic cap. Symptomatic manifestations of atherosclerosis begin when the fibrotic cap 
impedes blood flow, leading to angina, myocardial infarction, and stroke [4,17]. 
Multiple risk factors and pathological stimulants are involved in the pathogenesis of 
atherosclerosis ,including hemodynamic forces, classical cardiovascular risk factors (hyperlipidemia, 
hyperglycemia and psychologic stress), smoking, diet, environmental factors, and genetics [18,19]. 
Epigenetics is the study of heritable chromatin modifications that control gene expression by 
changing the accessibility of DNA or chromatin structure [3,20]. Epigenetic changes, including post‐
translational modification of nuclear proteins, are involved in the initiation and progression of 
atherosclerosis. These modifications are dynamic and reversible and are potential targets for anti‐
atherosclerotic drugs. 
2. Small Ubiquitin-Like Modifier (SUMO) Proteins and the Process of SUMOylation 
Post‐translational modifications (PTMs) are covalent, enzymatically catalyzed, modifications of 
proteins that result in functional changes. To date, more than 200 types of PTMs have been described 
in eukaryotes and prokaryotes, including ubiquitination, SUMOylation, phosphorylation, 
glycosylation, acetylation, and methylation [21–25]. 
PTM by SUMOylation is a critical regulator of the molecular, cellular and systemic functions of 
proteins. Small ubiquitin‐like modifier (SUMO) protein is a member of the ubiquitin‐like (Ubl) family 
with a molecular weight of 10KDa and four isoforms (1, 2, 3, and 4) in humans [26–29]. SUMO1 and 
SUMO2 have 50% sequence identity, whereas SUMO2 and SUMO3 have 97% similarity. Types 1, 2, 
and 3 are expressed ubiquitously, but SUMO4 is only found in the kidney, lymph nodes, and spleen 
[29–33]. 
The binding of SUMO to the target substrate is similar to the ubiquitination process and occurs 
via three distinct steps. First, attachment of SUMO to the E1 activating enzyme (SAE1/SAE2) in an 
ATP‐dependent reaction leads to its activation. Then, activated SUMO is transferred to Ubc9, which 
is a member of the family of conjugating enzymes known as E2. Finally, Ubc9 targets the SUMO 
resulting in binding to the specific substrate that is covalently attached to an E3 ligase (PIAS (protein 
inhibitor of activated STAT), RanBP2 (Ran‐binding protein 2), Pc2 (polycomb protein 2)). 
SUMOylation is a dynamic and reversible process, and SUMO‐specific peptidase enzymes (SENP 1, 
2, 3, 5, 6, 7) catalyze the deSUMOylation reaction that detaches the SUMO that bond to the lysine 
residue of target proteins [28,30,34–38] (Figure 1). 
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Figure 1. Schematic summary of the SUMOylation pathway. The precursor of small ubiquitin‐like 
modifier (SUMO) is matured by a member of the sentrin‐specific protease (SENP) family. This form 
has a C‐terminal di‐glycine motif. SUMO is then activated by E1 enzyme, a heterodimer of Aos1 and 
Uba2. Activated SUMO is passed to the active site of E2 conjugation enzyme, Ubc9. Finally, SUMO is 
transferred with E3 ligase to the target protein. DeSUMOylation of the substrate is caused by SENP 
family proteases. 
SUMOylation can alter protein conformation and influence the surface interactions of target 
proteins. SUMOylation affects cellular functionality and regulates various cellular processes 
including intracellular trafficking, subcellular localization, protein–protein interactions, cell cycle 
progression, DNA repair and replication, RNA metabolism, apoptosis, protein stability, and the 
activity of kinases [26,28,32,39–42]. 
3. Blood Flows and Atherosclerosis 
The inner surface of blood vessels is lined by a monolayer of endothelial cells that are constantly 
exposed to flow‐derived forces including frictional force (hemodynamic shear stress), stretch, and 
hydrostatic pressure [43–47]. In large arteries, atherosclerotic plaques predominantly occur in regions 
in which blood flow is slow or disturbed. This localization suggests that local blood flow patterns 
have a crucial role in the formation and progression of atherosclerotic plaques. It has been 
demonstrated that different flow‐patterns can modulate the structure and function of endothelial 
cells (ECs) and regulate the activation of pro‐inflammatory and pro‐apoptotic genes in ECs [17,47–
49]. 
Blood‐flow patterns include steady laminar flow (s‐flow) and disturbed flow (d‐flow). S‐flow 
stimulates ECs to secrete factors that are inhibitors of coagulation, leukocyte inflammation, and 
smooth muscle cell proliferation as well as promotion of ECs survival [43,50]. Based on the 
observation that atherosclerotic plaques are rare in regions exposed to s‐flow, it seems that this 
pattern of flow is anti‐atherogenic. On the other hand, d‐flow induces inflammation, apoptosis, 
proliferation of ECs and limited vascular reactivity. Most atherosclerotic plaques are located in 
regions of the arteries exposed to d‐flow, such as curved regions. Because d‐flow is pro‐atherogenic 
and s‐flow is anti‐atherogenic, an understanding of molecular signalling pathways which induces by 
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different types of flow and influences on ECs are critical. For example, long‐term stable flow up‐
regulates athero‐protective and antioxidant genes such as KLF2, eNOS. Conversely, d‐flow induces 
apoptosis, pro‐inflammatory genes, and results in hotspots of ECs with enhanced permeability and 
inflammation [51–54]. 
4. NFκB is a Regulator of Inflammation in ECs and a SUMOylation Target 
EC dysfunction leads to pathological inflammation, apoptosis and enhanced cell permeability. 
Atherogenesis occurs as a result of leukocyte recruitment. The release of cytokines and the expression 
of adherence molecules are regulated by NFκB [28]. The NFκB family is a group of five transcription 
factors: p65 (relA), relB, c‐Rel, p100/p52, and p100/p52. In its inactive state, NFκB is found in the 
cytoplasm bound to an inhibitor of κB (IκB). Activation of NFκB occurs when IκB kinase (IκK) is 
stimulated by an inflammatory factor (such as cytokines or d‐flow) IκK phosphorylates IκB and leads 
to its inactivation via ubiquitination tumorigenesis and inflammatory and cardiovascular disorders 
[55]. The resultant free NFκB translocates to the nucleus and trans‐activates pro‐inflammatory genes 
including VCAM‐1, E‐selectin, IL‐8, IL‐1, TNF, and ICAM‐1 [56]. 
SUMOylation has been shown to regulate NFκB through a variety of mechanisms. Modification 
of the NFκB precursor (p100) activates non‐canonical signalling pathways [57]. IκK is a complex of 
two kinases (IκK1 or IκKα and IκK2 or IκKβ) with a subunit called “NFκB essential modulator” 
(NEMO) or IκKγ. NEMO has no catalytic activity but is essential for IκK activation and IκB 
phosphorylation. Deletion of NEMO prevents IκK from efficiently phosphorylating IB and activating 
NFκB signalling [30,58]. Gareus and colleagues have demonstrated that endothelium‐specific 
depletion of NEMO or dominant‐negative IκBα inhibits the formation of atherosclerotic plaque. This 
observation demonstrates the crucial role of the NFκB signalling pathway in the pathogenesis of 
atherosclerosis [59]. It has recently been reported that modification of IκBα by SUMO1 inhibits its 
ubiquitination and destruction and down‐regulates NFκB activation. In contrast, Modification of 
IκBα by SUMO2/3 has the opposite effect and leads to the detachment of IκBα from NFκB and 
activation of this pathway [28,33,60]. Furthermore, investigations by Miyamoto et al. have 
demonstrated that genotoxic stress‐induced NEMO SUMOylation by SUMO1 results in up‐
regulation of IκK‐NFκB. Interestingly, SENP2 deSUMOylating enzyme, which is a transcriptional 
target downstream of NFκB, provides a negative feedback mechanism for NFκB activation via 
NEMO deSUMOylation. Additionally, deSUMOylation of NEMO in K277 via SENP6 inhibits TLR‐
induced inflammation [27,61–64]. 
5. Other Targets of SUMOylation Involved in the Pathogenesis of Atherosclerosis. 
5.1. MAPK-Activated Protein Kinase-2 (MK2) 
MK2 is a pro‐inflammatory kinase that increases NFκB activity by blocking the nuclear retention 
of p38 and inhibiting phosphorylation of mitogen‐ and stress‐activated protein kinase 1 (MSK1). It 
has been reported that MK2 depletion significantly inhibits TNFα‐induced inflammatory responses 
in ECs and plaque formation in LDLR‐/‐ mice with decreased expression of VCAM‐1 and MCP‐1. 
This observation demonstrates that activation of MK2 in ECs is a pro‐atherogenic event. 
SUMOylation of MK2 K339 inhibits its kinase activity, prevents actin filament remodelling and 
TNFα‐mediated ECs migration. While the exact role of SUMO modification of MK2 is unclear, it may 
be an important regulator of EC function [33,65,66]. 
5.2. ERK5 
Mitogen‐activated protein kinases (MAPKs) are a family of serine/threonine kinases that 
regulate various cellular functions such as proliferation, differentiation, survival, and apoptosis. The 
MAPK family includes four major subfamilies, of which ERK5 is one of the most important [43]. ERK5 
(also called MAPK7) has pivotal roles in endothelial hemostasis and has a unique role in protection 
against atherosclerosis because it is both a kinase enzyme and a transcription co‐activator. As with 
all MAPKs, ERK5 requires phosphorylation on Thr‐X‐Thr motif for activation and has a trans‐
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activation motif at its C‐terminus that regulates anti‐inflammatory genes [51,67,68]. EC‐specific ERK5 
knockout mice show accelerated apoptosis, inflammation, and atherosclerosis plaque formation [69]. 
Activation of ERK5 occurs in response to s‐flow and induction of upstream MEK5α. Once 
activated, the arginine‐rich middle region binds to the PPARγ1hinge‐helix and upregulates the 
transcription activity of peroxisome proliferator‐activated receptor γ (PPARγ). Direct association of 
ERK5 and PPARγ leads to the release of SMRT1, a PPARγ‐corepressor that down‐regulates PPARγ 
transcriptional activity. ERK5‐PPARγ association mediated‐SMRT1 release leads to inhibition of 
TNF‐mediated NFκB activation and consequently to inflammatory responses [70–72]. It has also been 
demonstrated that ERK5 activation increases the transcriptional activity of PPARδ and leads to 
inhibition of heme oxygenase1‐induced inflammatory response. Moreover, MEK5α/ERK5 activation 
increases the transcriptional activity of myocyte enhancer factor‐2 (MEF‐2) which is a critical 
component of the transcriptional system that is required for the regulation of KLF expression and 
leads to reduced inflammation. The KLF family, especially KLF2 and KLF4, are targets of ERK5 and 
play an important role in vascular biology including the regulation of EC inflammation, vascular 
tone, and permeability [30,73,74]. 
Hyperglycemia, oxidative stress, and d‐flow are inducers of ERK5 SUMOylation and lead to 
dysfunction and inflammation of ECs. Under normal conditions, ERK5 is not SUMOylated, and 
SENP2 protects ECs by continuously removing this pathologic modification (ERK5 SUMOylation). 
SENP2 knockdown leads to increased ERK5 SUMOylation which induces apoptosis and 
inflammation. It is noteworthy that d‐flow affects ERK5 SUMOylation without altering the 
expression of SENP2 [66]. It has been shown that d‐flow induces apoptosis and inflammation via 
upregulation of ROS production. ROS induces endogenous ERK5 SUMOylation at lysine 6 and 22, 
leading to inhibition of the transcriptional activity of ERK5 in ECs. This SUMOylation‐mediated 
inhibition of ERK5 reduces the s‐flow‐mediated KLF2 promoter activity and consequently reduces 
the expression of KLF2 and eNOS in ECs. 
Interestingly, SUMOylation‐mediated negative regulation of ERK5 transcriptional activity is 
independent of the phosphorylation and kinase activity of ERK5. Similarly, the kinase activity of 
ERK5 is not influenced by ERK5 SUMOylation. It has been suggested that SUMOylation of ERK5 and 
kinase activity are regulated independently of its transcriptional activity [30,33,43]. 
5.3. P90 Ribosomal s6 Kinase (p90RSK) 
P90RSK is a well‐characterized serine/threonine kinase that is unique in having two different 
kinase functional domains, one at each end. This enzyme plays an important role in EC dysfunction 
in cardiovascular disorders induced by diabetes mellitus [69]. 
P90RSK specifically binds to the C‐terminus of ERK5 and phosphorylates the S496 residue, 
leading to activation of ECs and vascular reactivity and consequently increased expression of VCAM‐
1 and decreased eNOS. Additionally, p90RSK can modulate ERK5 SUMOylation in a SENP2‐
dependent pathway. Activation of p90RSK via d‐flow leads to SENP2‐T368 phosphorylation and 
nuclear export, which causes a reduction of the deSUMOylating activity of SENP2 and increases 
SUMOylation of p53 and ERK5 in the nucleus. Consequently, up‐regulation of apoptosis and 
inflammation occur [45,47,52] (Figure 2). Inhibition of the transactivation activity of ERK5 leads to 
reduced expression of anti‐inflammatory genes and causes ECs dysfunction. ECs‐specific p90RSK 
overexpression has been shown to initiate ECs dysfunction and plaque formation in mouse aorta, but 
this does not occur in dominant‐negative (DN)‐p90RSK mice. Furthermore, SENP2 depletion in DN‐
p90RSK mice changes the athero‐protective phenotype [47]. 
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Figure.2 Pro‐atherogenic effects of d‐flow on inflammation and apoptosis in the p90RSK‐dependent 
pathway. In the steady‐state (s‐flow), SENP2 enzyme deSUMOylate p53, and ERK5, which are key 
regulators of inflammation and apoptosis in ECs. Activation of p90RSK, as a result of disturbed flow 
(d‐flow) leads to SENP2 enzyme inhibition. p53 and ERK5 remain in the SUMOylated form, which 
exacerbates inflammatory conditions and promotes cell proliferation following a decrease in the rate 
of apoptosis. 
6. KLF 
The proliferation of vascular smooth muscle cell (VSMC) is promoted by cyclin‐mediated cell 
cycle progression and is inhibited by CDK inhibitors. This process plays a pivotal role in the 
pathogenesis of a variety of disorders including atherosclerosis, hypertension, and vascular 
aneurysms [75]. KLF is a family of transcription factors all contain zinc fingers. One member of the 
family, KLF4 has a crucial role in promoting the formation of pluripotent stem cells and is emerging 
as an important player in tumorigenesis and inflammatory and cardiovascular disorders. It has 
recently been demonstrated that KLF regulates VSMC proliferation and differentiation by multiple 
mechanisms [76–78]. 
SUMOylation enables KLF4 to have a dual role in transcription regulation in response to 
environmental and cellular stimulants. Non‐SUMOylated KLF4 is associated with p300 and acts as 
an activator of p21 transcription and a negative regulator of cell proliferation. In response to PDGF‐
BB challenge, Ubc9 promotes KLF4 SUMOylation. Consequently, co‐repressors, including NCoR, 
HDAC2, and LSD2, are recruited to the p21 promoter. Inhibition of p21 expression leads to the 
proliferation of VSMCs [79,80]. 
Conversely, KLF family members, especially KLF2 and KLF4, are targets of ERK5 that play a 
key role in the regulation of inflammation in ECs and vascular tone and permeability [67,74]. Both 
KLF2 and KLF4 are highly expressed by ECs and induced by s‐flow, but inhibited by d‐flow and 
diabetic mediators such as AGEs and H2O2. These factors inhibit inflammation by competing with 
CBP/p300 cofactor for binding sites on NFκB. Down‐regulation of NFκB transcription activity by 
KLF2/4 leads to attenuation of the expression of pro‐inflammatory mediators such as cytokines, 
chemokines and adherence molecules. Moreover, induction of KLF2/4 expression leads to up‐
regulation of eNOS expression which has vasodilation, anti‐inflammatory and anticoagulant effects. 
ERk5 activation leads to MEF2 transactivation and consequently down‐regulates KLF2/4 [73,81–83]. 
7. Membrane-Associated Guanylate Kinase with Inverted Domain Structure-1 (MAGI-1) 
Membrane‐associated guanylate kinase with inverted domain structure‐1 (MAGI‐1) is a scaffold 
protein with six PSD95/DiscLarge/ZO‐1 domains, one guanylate kinase domain, and two WW (rsp5) 
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domains that is widely expressed in a variety of tissues, although not in skeletal muscle. MAGI‐1 is 
associated with adherence junctions and is required for cell–cell adhesion and maturation of VE 
cadherin–mediated adherence junctions. Recently, a genome wide‐associated study (GWAS) showed 
an association between the MAGI‐1 locus and the severity of a variety of chronic inflammatory 
disorders [52,84–88]. 
It has been demonstrated that MAGI‐1 can simultaneously modulate EC activation and 
apoptosis induced by endoplasmic reticulum stress. These are crucial molecular events in 
atherogenesis and are regulated by MAGI‐1‐K931 SUMOylation. DeSUMOylation of MAGI‐1‐K931 
is required for nuclear translocation of p90RSK. Consequently, nuclear p90RSK phosphorylates 
ERK5‐S496 and SENP2‐T368 and exacerbates cellular inflammation. Depletion of MAGI‐1 
significantly inhibits d‐flow‐induced atherogenesis [45–47,69]. 
8. p53 
p53 tumor suppressor plays an important role in determining whether cells undergo apoptosis 
or cell cycle arrest in response to a variety of stresses. Elevated nuclear p53 and up‐regulation of pro‐
apoptotic genes and cell‐cycle regulators occurs as a cellular response to DNA damage or stress 
[89,90]. The role of p53 in atherosclerosis and the biology of flow‐sensitive ECs is complex. In human 
atherosclerotic plaques, elevated p53 has been observed in ECs, suggesting that p53 promotes 
atherosclerosis. Studies on transgenic mice have shown that p53 overexpression leads to 
inflammation and dysfunction in ECs via down‐regulation of the anti‐atherogenic factor KLF2. 
Interestingly, p53 overexpression does not exacerbate atherosclerosis in transgenic mice [91–93]. 
Another study demonstrated that p53 knockout increases susceptibility to atherosclerosis and 
decreases vascular cell turnover. These controversial results may reflect different roles of p53 in 
different cell‐types including ECs, smooth muscle cells, and macrophages [94–97]. 
In cultured ECs, exposure to d‐flow results in the export p53 from the nucleus to the cytoplasm. 
This process is regulated by PKCζ‐mediated p53 SUMOylation. This occurs because d‐flow leads to 
PKCζ activation via induction of reactive oxygen species (ROS) production; consequently, activation 
of the PKCζ occurs by interaction of its C‐terminal kinase domain with RING domain of PIASγ. The 
RING domain includes the SUMO ligase catalytic site. PIASγ‐PKCζ association may increase the 
enzymatic activity of PIASγ by altering its tertiary structure. PIASγ–PKCζ association up‐regulates 
p53 SUMOylation. SUMOylated p53 is then transported from the nucleus to the cytoplasm [98]. In 
the cytoplasm, p53 induces apoptosis via direct interaction with Bax and Bcl‐2, preventing the anti‐
apoptotic function of Bax/Bcl‐2 and leading to apoptosis of ECs [53,89,99]. 
It has also been demonstrated that SENPs have a role in the control of d‐flow‐induced 
SUMOylation of p53 and ERK5. Six isoforms of SENPs are found in humans, including SENP2.  
Knockout SENP2 mice experienced accelerated plaque formation and up‐regulation of inflammation 
and apoptosis in ECs. It appears that this deletion leads to elevated p53 and ERK5 SUMOylation 
[45,100,101]. 
9. Adenosine Monophosphate-Activated Protein Kinase (AMPK) 
AMPK is a stress‐activated kinase that controls cellular responses to a variety of stresses through 
regulation of metabolism, protein synthesis, autophagy, and apoptosis. The enzyme is composed of 
three subunits, including a catalytic (α) and two regulatory (β, γ) subunits. In unstressed cells, AMPK 
is localized in the cytoplasm, and it translocates to the nucleus after activation. AMPK can inhibit 
endoplasmic reticulum stress by reducing ROS production and eNOS activation [102–104]. 
The role of AMPK in the regulation of inflammation in ECs and atherogenesis is isoform‐
dependent. The α1 isoform is pro‐inflammatory, and the α2 is anti‐inflammatory. Decreased 
atherosclerotic plaques formation has been reported in AMPKα1‐/‐/ApoE‐/‐ knockouts, whereas it is 
increased in AMPKα2‐/‐/LDLR‐/‐ [105]. Rubio et al. demonstrated that SUMO2 modification of 
AMPKα2 activates this enzyme and protects it from being inactivated via ubiquitination. However, 
SUMOylation inhibits the activity of AMPKα1 [106]. 
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10. Liver Receptor Homolog-1 (LRH-1) 
LRH‐1 or NR5A2, also called fetoprotein transcription factor, is a member of the NR5A 
subfamily of nuclear receptors (NRs) that are highly expressed in the intestine and liver and that 
regulate diverse functions from the development of cholesterol to bile acid hemostasis [107]. The 
transcriptional activity of LRH‐1 is governed by multiple factors, including ligand binding and PTMs, 
which together dictate the interaction of the receptor and transcriptional co‐regulators [108–110]. 
These receptors are targeted by E3‐SUMO ligase for SUMOylation at various lysine residues that 
affect their transcriptional activity. Modification of this receptor by SUMO1 has been demonstrated 
at lysine 224 located in hinge region of receptor. SUMOylation of human LRH‐1 decreases its 
transcriptional activity through a mechanism that is not yet fully understood. It has been shown that 
SUMOylation resulted in sequestration the receptor with promyelocytic leukemia (PML) protein 
bodies. It has been suggested that that SUMO modification of LRH‐1 leads to stable recruitment of 
transcriptional nuclear receptor corepressor‐1 and histone deacetylase 3 (NCoR1/HDAC3) 
corepressor complex and association to G protein pathway suppressor 2 (GPS2) [111–114]. 
Recently, Stein et al. demonstrated that modification of lysine 289 of LRH‐1 by SUMOylation 
plays a key role in the formation of atherosclerotic plaques. LRH‐1 K289R mice (mutant lysine 289) 
experience reduced SUMOylation of LRH‐1. Loss of SUMOylation in K289 is sufficient for cholesterol 
transport and protection of mice against atherosclerosis [108]. 
11. Conclusion 
Several studies have shown that epigenetic modifications contribute to the initiation and 
progression of atherosclerosis. Among these modifications, SUMOylation and SUMO protein 
modifications play important roles in the pathogenesis of atherosclerosis. SUMOylation affects 
various proteins and pathways including NFκB, ERK, p53, p90RSK, ERK, KLF, MK2, MAGI‐1, 
AMPK, and LRH‐1 which are pivotal regulators of the function of ECs (Table 1). Thus, dysregulated 
SUMO contributes substantially to the development of atherosclerosis. The development of research 
tools to study SUMOylation and the increasing number of in vivo and in vitro studies in this area 
have expanded our understanding of the role of the SUMOylation in these pathways. The crucial role 
of SUMO and SUMOylation in the formation of atherosclerotic plaques presents a novel therapeutic 
target in the management of atherosclerosis. Further work is required to develop and evaluate 
therapeutic agents that modulate SUMOylation and that can be used in the prevention and 
management of atherosclerosis. 
Table 1. Summary of factors that affected by SUMO modifications and are involved in atherosclerosis 
pathogenesis. 
Protein 
General characteristics and association with 
pathogenesis of atherosclerosis  
Consequences of SUMO 
modifications 
Ref 
NFκB 
A family of transcriptional factors localized in the 
cytoplasm in the inactive form that require 
stimulation by an inflammatory factor to enable  
nuclear localization and subsequent activation of 
pro‐inflammatory genes involved in atherogenesis  
Down‐regulation of NFκB 
pathway by SUMO1 modification 
of IκBα 
Up‐regulation of NFκB pathway 
by SUMO2/3 modification of IκBα 
[28,56,57] 
MK2 
A pro‐inflammatory kinase that increases NFκB 
activity 
Inhibition of its kinase activity by 
K339 SUMOylation 
[33,66,67] 
ERK5 
A family of serine/threonine kinases that regulates 
various cellular functions especially in endothelial 
hemostasis and is protective against atherosclerosis 
D‐flow‐induced ERK5 
SUMOylation and EC dysfunction  
[43,51,67–69] 
p90RSK 
A serine/threonine kinase associated with EC 
dysfunction in diabetes mellitus‐induced 
cardiovascular disorders 
Phosphorylation and consequent 
inhibition of SENP2 
deSUMOylating enzymes which 
blocks activation of ERK5 and p53 
genes  
[33,70] 
KLF 
A family of transcription factors that play an 
important role in inflammatory and cardiovascular 
disorders 
SUMOylation of KLF4 leads to 
recruitment of co‐repressors to the 
[68,75,80,81] 
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KLF4 is a member of this family which acts as a 
negative regulator of cell proliferation via p21 
interaction in non‐SUMOylated state 
 
p21 promoter and increases the 
proliferation of VSMCs  
MAGI‐
1 
A scaffold protein that is associated with adherence 
junctions and modulates crucial molecular events in 
atherogenesis including the activation of ECs and 
endoplasmic reticulum stress‐induced apoptosis.  
DeSUMOylation of MAGI‐1‐K931 
is required for nuclear 
translocation of p90RSK 
[52,87] 
p53 
An important tumor suppressor that plays a role in 
determining the fate of cell for apoptosis or cell 
cycle arrest in response to various stresses 
SUMOylated p53 exports from 
nucleus to the cytoplasm and 
induces ECs apoptosis via direct 
interaction by pro‐apoptotic 
proteins 
[33,90,91,102,103] 
AMPK 
A stress‐activated kinase that orchestrates cellular 
responses to different stresses 
AMPKα2 activation and protection 
from UQ destruction via SUMO2 
modification 
AMPKα1 inhibition via 
SUMOylation 
[106–108,110] 
LRH‐1 
A member of NR5A subfamily for nuclear receptors 
with various functions such as cholesterol and bile 
acid hemostasis 
Association of K289 LRH‐1 
SUMOylation and atherosclerosis 
pathogenesis 
[111,112] 
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